Effect and tolerability of blonanserin in severe delusion with various types of dementia

Manabu Takaki; Hajime Honda; Seishi Terada; Yosuke Uchitomi

doi:10.1111/psyg.12090

Effect and tolerability of blonanserin in severe delusion with various types of dementia

Manabu Takaki, Hajime Honda, Seishi Terada, Yosuke Uchitomi

Research output: Contribution to journal › Article › peer-review

Abstract

Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D₂ receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D₃ receptor-blocking activities and weak 5-hydroxytryptamine-2C, α₁-, histamine H₁-, and muscarinic M₁-blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia. Psychogeriatrics

Original language	English
Pages (from-to)	144-146
Number of pages	3
Journal	Psychogeriatrics
Volume	15
Issue number	2
DOIs	https://doi.org/10.1111/psyg.12090
Publication status	Published - Jun 1 2015

Keywords

Blonanserin
D receptor
Delusion
Dementia
Hallucination

ASJC Scopus subject areas

Gerontology
Geriatrics and Gerontology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/psyg.12090

Cite this

@article{55fb4001f99540c899a27d3842dcaa53,

title = "Effect and tolerability of blonanserin in severe delusion with various types of dementia",

abstract = "Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D2 receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D3 receptor-blocking activities and weak 5-hydroxytryptamine-2C, α1-, histamine H1-, and muscarinic M1-blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia. Psychogeriatrics",

keywords = "Blonanserin, D receptor, Delusion, Dementia, Hallucination",

author = "Manabu Takaki and Hajime Honda and Seishi Terada and Yosuke Uchitomi",

note = "Publisher Copyright: {\textcopyright} 2014 Japanese Psychogeriatric Society.",

year = "2015",

month = jun,

day = "1",

doi = "10.1111/psyg.12090",

language = "English",

volume = "15",

pages = "144--146",

journal = "Psychogeriatrics",

issn = "1346-3500",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Effect and tolerability of blonanserin in severe delusion with various types of dementia

AU - Takaki, Manabu

AU - Honda, Hajime

AU - Terada, Seishi

AU - Uchitomi, Yosuke

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D2 receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D3 receptor-blocking activities and weak 5-hydroxytryptamine-2C, α1-, histamine H1-, and muscarinic M1-blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia. Psychogeriatrics

AB - Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D2 receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D3 receptor-blocking activities and weak 5-hydroxytryptamine-2C, α1-, histamine H1-, and muscarinic M1-blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia. Psychogeriatrics

KW - Blonanserin

KW - D receptor

KW - Delusion

KW - Dementia

KW - Hallucination

UR - http://www.scopus.com/inward/record.url?scp=84930762892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930762892&partnerID=8YFLogxK

U2 - 10.1111/psyg.12090

DO - 10.1111/psyg.12090

M3 - Article

AN - SCOPUS:84930762892

VL - 15

SP - 144

EP - 146

JO - Psychogeriatrics

JF - Psychogeriatrics

SN - 1346-3500

IS - 2

ER -

Effect and tolerability of blonanserin in severe delusion with various types of dementia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this